A 62-year-old male smoker presents with central chest pain, cough, and hemoptysis. Chest X-ray shows a hilar mass with mediastinal widening. Bronchoscopic biopsy reveals small round cells with scant cytoplasm, fine chromatin, and numerous mitoses. Immunohistochemistry is positive for synaptophysin and chromogranin A. All of the following are true regarding this patient's condition EXCEPT:

Question

Accepted Answer

D. The tumor arises from squamous metaplasia of the bronchial mucosa and has a better prognosis than adenocarcinoma of the lung. ## Small Cell Lung Cancer: Clinical Features and Management

### Diagnosis and Neuroendocrine Origin
**Key Point:** The clinical and histopathologic findings (small round cells, fine chromatin, high mitotic rate, positive synaptophysin and chromogranin A) confirm small cell lung cancer (SCLC). SCLC arises from **neuroendocrine (Kulchitsky) cells**, NOT from squamous metaplasia. Squamous metaplasia is associated with NSCLC (squamous cell carcinoma) [cite:Robbins 10e Ch 15].

### Paraneoplastic Syndromes
**High-Yield:** SCLC is the **most common lung cancer associated with paraneoplastic syndromes** (30–50% of cases):
- **SIADH** (most common; hyponatremia)
- **LEMS** (antibodies against voltage-gated calcium channels; proximal weakness, autonomic dysfunction)
- Cushing syndrome (ectopic ACTH)
- Myasthenia gravis
- Sensory neuropathy

These may precede the diagnosis of cancer [cite:Harrison 21e Ch 111].

### Chemotherapy Response and Prognosis
**Clinical Pearl:** SCLC is **exquisitely chemosensitive** — initial response rates to platinum-etoposide are 60–80%. However, **long-term remission is uncommon**, and most patients relapse within 6–12 months. Median survival: limited disease 9–11 months, extensive disease 4–6 months.

### Prophylactic Cranial Irradiation (PCI)
**Key Point:** PCI is **standard of care** for patients with SCLC who achieve complete remission (CR), reducing brain metastasis incidence from ~40% to ~15% and improving overall survival by ~5% [cite:Harrison 21e Ch 111].

### Why Option 4 Is Incorrect
**Warning:** SCLC arises from **neuroendocrine cells**, not squamous metaplasia. Squamous cell carcinoma (a type of NSCLC) arises from squamous metaplasia. Additionally, SCLC has a **worse prognosis** than adenocarcinoma of the lung (5-year survival SCLC ~7% vs. adenocarcinoma ~20%).

| Feature | SCLC | Squamous Cell CA | Adenocarcinoma |
| --- | --- | --- | --- |
| **Cell origin** | Neuroendocrine | Squamous metaplasia | Mucus-secreting cells |
| **5-year survival** | ~7% | ~15% | ~20% |
| **Paraneoplastic syndromes** | Common (30–50%) | Rare | Rare |
| **Initial chemo response** | Excellent (60–80%) | Moderate | Moderate |

Answer

A. The tumor is likely to respond well to initial platinum-based chemotherapy, but long-term remission is uncommon

Answer

B. Paraneoplastic syndromes such as syndrome of inappropriate antidiuretic hormone (SIADH) and Lambert-Eaton myasthenic syndrome (LEMS) are common and may precede the diagnosis

Answer

C. Prophylactic cranial irradiation (PCI) is indicated in patients who achieve complete remission to reduce brain metastasis risk

Explanation

Small Cell Lung Cancer: Clinical Features and Management

Diagnosis and Neuroendocrine Origin

Paraneoplastic Syndromes

Chemotherapy Response and Prognosis

Prophylactic Cranial Irradiation (PCI)

Why Option 4 Is Incorrect

Practice similar questions

Join our NEET PG community

Feature	SCLC	Squamous Cell CA	Adenocarcinoma
Cell origin	Neuroendocrine	Squamous metaplasia	Mucus-secreting cells
5-year survival	~7%	~15%	~20%
Paraneoplastic syndromes	Common (30–50%)	Rare	Rare
Initial chemo response	Excellent (60–80%)	Moderate	Moderate